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Objectives We sought to develop a new bioactive gas-delivery method by the use of echogenic liposomes (ELIP) as the gas
carrier.
Background Nitric oxide (NO) is a bioactive gas with potent therapeutic effects. The bioavailability of NO by systemic delivery
is low with potential systemic effects.
Methods Liposomes containing phospholipids and cholesterol were prepared by the use of a new method, freezing under
pressure. The encapsulation and release profile of NO from NO-containing ELIP (NO-ELIP) or a mixture of NO/
argon (NO/Ar-ELIP) was studied. The uptake of NO from NO-ELIP by cultured vascular smooth muscle cells
(VSMCs) both in the absence and presence of hemoglobin was determined. The effect of NO-ELIP delivery to at-
tenuate intimal hyperplasia in a balloon-injured artery was determined.
Results Coencapsulation of NO with Ar enabled us to adjust the amount of encapsulated NO. A total of 10 l of gas can
be encapsulated into 1 mg of liposomes. The release profile of NO from NO-ELIP demonstrated an initial rapid
release followed by a slower release during the course of 8 h. Sixty-eight percent of cells remained viable when
incubated with 80 g/ml of NO/Ar-ELIP for 4 h. The delivery agent of NO to VSMCs by the use of NO/Ar-ELIP was
7-fold greater than unencapsulated NO. We discovered that NO/Ar-ELIP remained an effective delivery agent of NO to
VSMCs even in the presence of hemoglobin. Local NO-ELIP administration to balloon-injured carotid arteries attenu-
ated the development of intimal hyperplasia and reduced arterial wall thickening by 41  9%.
Conclusions Liposomes can protect and deliver a bioactive gas to target tissues with the potential for both visualization of
gas delivery and controlled therapeutic gas release. (J Am Coll Cardiol 2009;54:652–9) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.039A
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litric oxide (NO) is a potent bioactive gas with vasodilatory,
nti-inflammatory, antithrombotic, antiproliferative, and pos-
ibly antiatherogenic properties (1,2). The desirable character-
stics of NO in modulating the development of various vascular
iseases have prompted the development of various NO
recursors, synthetic NO promoters such as L-arginine, endo-
helial NO synthase gene, NO donors, and NO gas. One of
he most popular methodologies for NO gas delivery clinically
s via inhalation (3–5). In 1999, the U.S. Food and Drug
rom the *Division of Cardiology, Department of Internal Medicine, The University
f Texas Health Science Center at Houston, Houston, Texas; and the †Department
f Biochemistry, Molecular Biology and Cell Biology, Northwestern University,
vanston, Illinois. This work was supported in part by National Institutes of Health
rants (R01 HL-74002 and R01 HL-059586 to Dr. McPherson) and an American
eart Association Award (0535512Z to Dr. Huang).e
Manuscript received January 6, 2009; revised manuscript received March 18, 2009,
ccepted April 13, 2009.dministration approved an inhaled formulation of NO gas
or the treatment of patients with persistent pulmonary arterial
ypertension (6). Another potential use of NO would be to
odulate neointimal hyperplasia (7). Although the delivery
f NO to the arterial wall has a number of potential
enefits, successful NO delivery to targeted tissues is
hallenging because of the presence of endogenous NO
cavengers such as hemoglobin (5).
Our laboratory has developed a number of liposomal for-
ulations for molecular imaging and drug and gene delivery
8–12). The encapsulation of air into these liposomal formu-
ations results in a contrast agent that is suitable for ultrasound
mage enhancement and is stable in serum at 37°C for a
rolonged duration (9). In this study, we demonstrated that
ases such as NO can also be encapsulated into our echogenic
iposomes (ELIP), resulting in a “theranostic” agent with both
chogenic and bioactive gas-delivery properties.
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653JACC Vol. 54, No. 7, 2009 Huang et al.
August 11, 2009:652–9 NO Liposomes for Hyperplasia InhibitionThe specific aims of this study were to: 1) encapsulate NO
nto ELIP; 2) adjust the encapsulated gaseous composition by
he inclusion of argon (Ar) to modulate the rate of NO release;
) determine the protective effects of NO encapsulation into
LIP for delivery to vascular smooth muscle cells (VSMCs) in
itro in the presence of hemoglobin, an endogenous NO
cavenger; and 4) demonstrate the potential therapeutic effects
f NO delivery from NO/Ar-ELIP in attenuating neointimal
yperplasia in injured common carotid arteries of cholesterol-fed
abbits.
ethods
reparation of NO-containing liposomes (NO-ELIP) and
O/Ar-containing liposomes (NO/Ar-ELIP). We used li-
osomes composed of 1,2-dipalmitoyl-sn-glycero-3-
thylphosphocholine (Genzyme Corporation, Cambridge,
assachusetts); 1,2-dioleoyl-sn-glycero-3-phosphocholine
Avanti Polar Lipids, Alabaster, Alabama); and cholesterol
Avanti Polar Lipids) at a mole ratio of 60:30:10. Lipo-
omes were made by the previously developed pressured-
reeze method with modification (13). In brief, after drying
nd hydrating lipid film, the liposomes were transferred to a
-ml glass vial with a cap that was sealed with a Teflon-
ubber septum. Then, NO (specialty gases of America, Inc.,
oledo, Ohio) was washed and deoxygenated with a satu-
ated NaOH solution. Ten milliliters of NO alone or a
aseous mixture of NO and Ar was injected into the glass
ial through the Teflon-rubber septum by the use of a 12-ml
yringe attached to a 27-G, 0.5-inch needle. The pressur-
zed liposomal dispersion was frozen at 70°C with dry ice
or at least one-half hour. The pressure in the vial was
eleased by the removal of the cap, and the liposomal
ispersion was allowed to thaw. Gas encapsulation, release
rofiles, and delivery characteristics of NO-ELIP or NO/
r-ELIP were studied after thawing. The volume of en-
apsulated gas in liposomes was measured by the use of a
yringe method as previously described (12).
he NO release study. The release of NO from pure
O-ELIP and NO/Ar-ELIP was determined by serial dial-
sis under sink conditions. A dispersion of 20 l of NO-ELIP
nd 180 l of phosphate-buffered saline (PBS) (donor buffer)
as placed inside a dialysis tube (MWCO:12-14,000, Spec-
rum Laboratories, Inc., Rancho Dominguez, California) and
ialyzed against 1 ml of PBS (receiving buffer). The dialysis
ube was transferred to a fresh PBS solution and the release
f NO was measured at 5, 10, 20, 30, 60, 120, 240, and 480
in. The measurement of NO release from NO-ELIP
nto the receiving buffer was based on the reaction
etween NO and oxygen to yield nitrite (4NO  O2 
H2O ¡ 4NO2
  4H) (14). The nitrite concentration
n the receiving solution was measured with a colorimetric
O assay kit (BioVision Inc., Mountain View, California).
ecause NO can exist in 2 different compartments in the
ialysis system, namely encapsulated NO inside NO-ELIP
r dissolved NO in the surrounding solution, NO-saturated dannitol solution was used as a
ontrol to correct for NO release
rom NO-ELIP. Thus, the nitrite
oncentration in the receiving
uffer with the NO-ELIP or NO/
r-ELIP subtracted by the nitrite
oncentration in the receiving so-
ution with the mannitol was taken
o be equivalent to the NO released
rom NO-ELIP or NO/Ar-ELIP
t each time point.
ell viability in the presence
f NO/Ar-ELIP. Rat VSMCs
ere grown in 75-cm2 flasks con-
aining a medium of Dulbecco
odified Eagle medium (DMEM)
GIBCO-BRL, Grand Island, New
ork) and 10% fetal bovine serum
FBS), 100 U/ml penicillin and 100
g/ml streptomycin at 37°C under
% CO2 and 95% air. Cells ob-
ained between passages 5 and 8
ere used.
Twenty-four hours before the experiment, rat VSMCs
ere seeded in 48-well plates in DMEM and 10% FBS.
he medium was removed and replaced with a solution
ontaining DMEM and 0.3% FBS. The concentration of
BS was decreased to minimize the interference with the
O assay. Differing concentrations of NO/Ar-ELIP were
dded to VSMC and incubated at 37°C for 4 h. After
ncubation, the medium was removed, and the cells were
ashed twice with PBS. Cell viability was measured with a
ommercially available calcein AM kit (Calbiochem, Gibbs-
own, New Jersey).
elivery of NO into VSMCs. Thirty microliters of
O/Ar (1:9)-ELIP or NO/Ar saturated mannitol solution
ere incubated with cultured VSMCs in a 48-well plate for
min. The solutions were aspirated and VSMC were
ashed 3 times with 500 l of PBS solution. The uptake of
O by VSMC was determined by measuring the nitrite
oncentration in cultured cells by use of the NO assay kit. In
rief, in this reaction, nitrate reductase in the VSMC
onverts nitrate to nitrite. Nitrite then reacts with the
hromogenic substrate, sulfanilamide, and N-(1-naphthyl)
thylenediamine to produce a color reaction that was deter-
ined according to the optical density at 540 nm (OD540)
ith a Tecan microplate reader (Tecan US Inc., Raleigh,
orth Carolina).
elivery of NO in the presence of hemoglobin. The
ptake of NO by VSMCs in the presence and absence of
emoglobin was measured by the NO-fluorescent probe
iaminofluorescein-2 diacetate (DAF-2DA, Calbiochem)
o localize NO production in cells by fluorescence micros-
opy. The probe DAF-2DA is a nonfluorescent agent that
an readily diffuse into cells and be converted into
Abbreviations
and Acronyms
Ar  argon
CH  cholesterol
DAF-2DA 
diaminofluorescein-2
diacetate
DMEM  Dulbecco’s
modified Eagle medium
ELIP  echogenic
liposomes
FBS  fetal bovine serum
NO  nitric oxide
NO/Ar-ELIP  nitric oxide/
argon-containing liposomes
NO-ELIP  nitric oxide-
containing liposomes
PBS  phosphate-buffered
saline
VSMC  vascular smooth
muscle celliaminofluorescein-2 by cytosolic esterase inside living cells.
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NO Liposomes for Hyperplasia Inhibition August 11, 2009:652–9hen NO is delivered into VSMC, NO reacts with
iaminofluorescein-2, a nonfluorescent dye, to generate
iaminofluorescein-2 triazole, a fluorescent product. In the
resence or absence of 1 mg/ml of hemoglobin, VSMCs
ere incubated with 30 l of NO/Ar-ELIP or NO satu-
ated mannitol solution for 5 min. The incubating solution
as removed, and VSMCs were washed 3 times with PBS.
en microliters of DAF-2DA working solution (1:500 dilu-
ions in PBS) were added to VSMC and incubated for 30 min
n the dark. The DAF-2DA was removed and the VSMCs
ere washed 3 times with PBS. The uptake of NO by VSMCs
nder different conditions was qualitatively assessed by fluo-
escence microscopy at wavelength of 495 nm.
alloon injury and local delivery of NO/Ar-ELIP
n vivo. All animal experiments were approved by the
nimal Welfare Committee at the University of Texas
ealth Science Center at Houston. Twenty-one male New
ealand White rabbits weighing 3.0 to 4.5 kg were used.
he animals were fed an atherogenic diet, containing 0.2%
holesterol and 4% coconut oil for 2 weeks before balloon
enudation. On the day of surgery, the rabbit was anesthe-
ized with ketamine (35 mg/kg), xylazine (5 mg/kg), and 1%
o 3% isoflurane. Balloon injury to the common carotid
rtery was performed using a 2-F Fogarty catheter (Edwards
ifesciences, Irvine, California).
A sheath was inserted into the right external carotid
rtery, and the catheter was introduced through the sheath
nto the common carotid artery. The balloon was inflated
ith 200 l of saline solution and passed back and forth for
times in the common carotid artery over a distance of 3
m. Immediately after balloon injury, liposomes containing
r alone or a gaseous mixture of 10% NO and 90% Ar was
Figure 1 NO Release Profile
Illustrated is the amount of released NO when pure NO (open circles) or a mix-
ture of 20% NO with 80% Ar (closed circles) were encapsulated into the lipo-
somes. NO  nitric oxide; NO/Ar-ELIP  nitric oxide/argon-containing
liposomes; NO-ELIP  nitric oxide-containing liposomes.njected locally into the distally occluded common carotidrtery through the sheath and allowed to dwell for 2 min.
he occluding suture was then released, the sheath re-
oved, the external carotid artery ligated, the wound closed,
nd the rabbit allowed to recover. Carotid arteries subjected
o a sham procedure, balloon-injured carotid arteries with-
ut treatment, and contralateral common carotid arteries
ithout injury or treatment were used as controls.
The animals continued on a high cholesterol diet and were
acrificed 2 weeks after surgery. The carotid arteries were
emoved, cut into 2.5-mm segments, and fixed with PBS
ontaining 4% formalin for 24 h. The fixed tissues were
mbedded in paraffin and sections were stained with hematox-
lin and eosin for histologic examination. All sections from the
njured segment of each artery were examined in a blind
ashion using Image-Pro Plus (Media Cybernetics, Bethesda,
aryland). Measurements were made of the cross-sectional
rea of the lumen and of the areas enclosed by the internal and
xternal elastic laminae. The intimal cross-sectional area of
arotid artery segments was determined by subtracting the area
f the lumen from the area enclosed by the internal elastic
amina. The medial area was determined by subtracting the
rea enclosed by the internal elastic lamina from the area
nclosed by the external elastic lamina.
tatistical analysis. Statistical analysis between groups was
erformed by a t test or one-way analysis of variance with the
se of SigmaStat (version 3.5, Systat Software Inc., Point
ichmond, California) and Statistica (version 8.0, StatSoft,
nc., Tulsa, Oklahoma) software. Differences between multiple
roups were assessed with the post-hoc Tukey HSD test for
nequal N. A value of p 0.05 was considered significant. All
ata are presented as mean  SEM.
esults
ncapsulation and release of NO. Ten microliters of NO
as were encapsulated into 1 mg of liposomes by use of the
Figure 2 Cell Viability With NO-ELIP
Vascular smooth muscle cell viability at 4 h after differing amounts of NO/Ar
(1:9)-containing liposomes. Viability was measured with the use of calcein AM.
Abbreviations as in Figure 1.
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August 11, 2009:652–9 NO Liposomes for Hyperplasia Inhibitionreezing under pressure method. The release of NO from
O-ELIP was rapid, with 50% of the encapsulated gas
eleased within 10 min, followed by slower release over 8 h
Fig. 1). In contrast, NO release was slower in the presence
Figure 3 NO Delivery Into Cultured
Vascular Smooth Muscle Cells
Cells were cultured in 48-well plates and incubated with NO/Ar (1:9)-saturated
mannitol (left) or 30 g of NO/Ar (1:9)-containing liposomes (right) for 10
min. The uptake of NO was expressed as nitrate and nitrite concentrations.
Abbreviations as in Figure 1.
Figure 4 Cellular Uptake of NO
Representative DAF-2DA fluorescence images of vascular smooth muscle cells tre
(B) NO/Ar (1:9)-containing liposomes in the absence of hemoglobin, (C) NO/Ar (1f Ar (liposomes containing 20% NO and 80% Ar). The
otal volume of releasable NO was 2 l from 1 mg 20%
O/80% Ar-containing liposomes, 1 l from 1 mg 10%
O/90% Ar-containing liposomes, and 10 l from 1 mg
O-ELIP. For the rest of our experiments, we used a
O/Ar ratio of 1 to 9, with a NO concentration of 0.045
mol/mg lipids.
ell viability in the presence of NO-ELIP. The effect of
he lipid and gaseous components of 10% NO and 90% Ar on
ell viability was evaluated by measuring the extent of calcein
M uptake in cultured VSMC. As shown in Figure 2, 68% of
ells remained viable after incubating with 0.08 mg/ml
O/Ar-ELIP (2 mol/l NO) for 4 h. Eighty-two percent
f the cells were viable in a culture media containing 0.01 to
.04 mg/ml NO-ELIP. We arbitrarily selected concentra-
ions in the range from 0.01 to 0.04 mg/ml (containing 0.26
o 1.0 M/l of NO) of NO/Ar-ELIP in subsequent in vitro
ell culture experiments because of the relatively high cell
iability and the substantial amount of NO that was
eliverable by NO/Ar-ELIP.
elivery of NO into cultured VSMCs. The uptake of
O by cells was measured on the basis of the corresponding
itrate and nitrite concentration by use of a colorimetric NO
ssay kit. The VSMCs were incubated with a solution
ontaining 30 g/ml NO/Ar-saturated mannitol or 30
g/ml NO/Ar-ELIP. The amount of NO that can be
ith (A) NO/Ar-saturated mannitol solution in the absence of hemoglobin,
urated mannitol solution in the presence of hemoglobin, and (D) NO/Ar (1:9)-ated w
:9)-sat
containing liposomes in the presence of hemoglobin. DAF-2DA  diaminofluorescein-2 diacetate; other abbreviations as in Figure 1.
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NO Liposomes for Hyperplasia Inhibition August 11, 2009:652–9elivered to cells was 7-fold greater with NO/Ar-ELIP
han with NO/Ar-saturated mannitol solution (Fig. 3).
Because hemoglobin is the primary scavenger of NO in
he circulation, which drastically reduces the bioavailability
f NO to target tissues, we evaluated the delivery of
O/Ar-ELIP in the presence of hemoglobin (Figs. 4C and
D). Cellular uptake of NO was visualized by DAF-2DA
uorometric imaging. In the absence of hemoglobin, both
he NO/Ar-saturated mannitol solution and the NO/Ar-
LIP efficiently delivered NO to VSMCs (Figs. 4A and
B). The fluorescence signal was stronger inside cells
ncubated with NO/Ar-ELIP than with the NO/Ar-
aturated mannitol solution. In the presence of hemoglobin,
O delivery to cells from NO/Ar-saturated mannitol solu-
ion was poor (Fig. 4C), whereas, that from NO/Ar-ELIP
as effective, as indicated by the bright cellular fluorescence
Fig. 4D).
ffects of local delivery of NO/Ar-ELIP on the devel-
pment of neointimal hyperplasia in balloon-injured
rteries. The combination of balloon denudation of the
arotid arteries and cholesterol feeding induced extensive
eointimal hyperplasia and luminal narrowing relative to
he uninjured arteries (Figs. 5A and 5B). The Ar-ELIP did
ot attenuate the hyperplastic reaction in balloon-injured
rteries (Fig. 5C). However, NO/Ar-ELIP was able to
nhibit the hyperplastic response in balloon-injured arteries
Figs. 5D and 6). Intima/media thickness ratios decreased
rom 1.1  0.39 in injured control animals without any
pecific treatment to 0.5  0.09 in animals treated with
Figure 5 NO/Ar-ELIP Effect on Inhibition of Neointimal Hyperpla
Representative histological sections of (A) normal common carotid artery (no ballo
artery 14 days after balloon injury treated with Ar-ELIP, and (D) common carotid ar
toxylin and eosin 400). Abbreviations as in Figure 1.O/Ar-ELIP (Fig. 6A). Similarly, the intimal area was
educed from 0.4 0.09 mm2 in the injured control animals to
.2 0.07 mm2 in the NO/Ar-ELIP-treated animals (n 9,
 0.05) (Figs. 6B and 5B vs. 5D). Ar-ELIP had no effect on
he intima/media thickness ratio or intimal area. The decrease
n intimal area induced by NO/Ar-ELIP accounted for the
ecrease in the arterial wall thickness (Table 1).
iscussion
mpaired endothelial NO production is implicated in many
ardiovascular diseases, such as essential hypertension,
troke, coronary artery disease, atherosclerosis, platelet ag-
regation and restenosis after percutaneous transluminal
oronary angioplasty, and ischemia/reperfusion injury
15,16). The administration of exogenous NO can poten-
ially supplement NO to the arterial wall and has been
xplored during the past decade as a therapeutic agent (16).
his study has demonstrated that encapsulation of a bioac-
ive gas, NO, into ELIP can be achieved with a freezing
nder pressure technique. The resultant NO-ELIP has a
iphasic release profile. The amount of releasable NO from
LIP can be modulated by mixing it with Ar, thus
rolonging NO delivery for in vivo applications. We clearly
emonstrate from in vitro, ex vivo, and animal models that
iposomal encapsulation of NO protects the payload against
O scavenging by hemoglobin and that effective NO
elivery by NO-ELIP inhibits intimal hyperplasia in injured
rterial segments. This is the first study to describe liposo-
ury), (B) common carotid artery 14 days after balloon injury, (C) common carotid
days after balloon injury treated with NO/Ar (1:9)-containing liposomes (hema-sia
on inj
tery 14
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August 11, 2009:652–9 NO Liposomes for Hyperplasia Inhibitional encapsulation of a bioactive gas for controlled release
ith in vivo biologic effects. We used NO as a model gas in
he current study, and this new methodology of gas encap-
ulation into liposomes can be applied to other therapeutic
ases.
iposome for bioactive gas entrapment and delivery. Patho-
ogical changes to vascular wall have been observed in
ardiovascular diseases such as atherosclerosis (17). Numer-
us pharmaceutics have been investigated to treat or prevent
therosclerosis. Gases can be thought of as small molecules
hat readily cross the endothelial barrier (18). The obstacles
f using bioactive gases for the treatment of other vascular
onditions have been related to the lack of suitable admin-
stration methods and potential adverse effects as the result
Figure 6 Quantitation of Neointimal Hyperplasia
(A) Intima/media thickness ratio and (B) intimal area of injured common
carotid arteries: control (left); treated with Ar-ELIP (middle); and treated with
NO/Ar (1:9)-containing liposomes (right). Abbreviations as in Figure 1.
orphometric Analysis of the Carotid Arteries 14 Days After BallooTable 1 Morphometric Analysis of the Carotid Arteries 14 Days
Treatment Group Intimal Area (mm2) Intimal Depth (mm)
Injury alone (n  8) 0.41 0.03 0.18 0.02
Ar-liposomes (n  5) 0.45 0.04 0.15 0.01
NO/Ar-liposomes (n  9) 0.24 0.02† 0.09 0.01*alues are mean  SEM. *p  0.05 versus injury alone and Ar-containing liposomes. †p  0.005 versus
AR  argon; I/M  intima/media; NO  nitric oxide.f systemic delivery. With our new methodology, we have
emonstrated that local delivery of NO-ELIP into carotid
rteries can inhibit intimal hyperplasia in a balloon-injured
rterial model.
The technique of freezing under pressure is effective in
ncapsulating precise amounts of NO in liposomes. With
his technique, we postulate that the increased concentra-
ions of NO dissolved in solution provide a means for the
ntrapment of NO in the hydrophobic bilayer of NO-ELIP
uring the freezing and thawing process (13). Nitric oxide is
colorless and odorless gas that readily reacts with oxygen
o form NO2 gas, which is toxic to cells. In our formula-
ions, we took special precautions to prevent NO from
eacting with oxygen because this interaction would have
esulted in the formation of toxic NO2. This precaution
ncluded mixing NO with an inert gas, Ar, and deoxygen-
ting all gases by passing them through a saturated solution
f sodium hydroxide.
The release of NO from NO-ELIP is rapid, and one-half
f the payload is released within the first 10 min followed by
n extended period of slower release over at least 8 h (Fig.
). Such a release profile is highly desirable when treating
cute arterial injury. In contrast, the other ELIP formula-
ion that contains a mixture of NO and Ar has slower NO
elease kinetics that may be suitable for clinical settings
hen chronic low level delivery is desirable.
Sixty percent of the lipid shell of NO-ELIP is comprised
f positively charged phospholipids, which are known to
acilitate attachment of liposomes and other lipid particles
o negatively charged endothelial surfaces and exposed
xtracellular matrix in damaged arteries. We have previously
emonstrated that our ELIP formulations are suitable for
arrying air and/or a variety of drugs such as papaverine
ydrochloride (19), azithromycin (20), tissue plasminogen
ctivator (21,22), and rosiglitazone (23). In the current
tudy, we demonstrated that 6 l of NO can be encapsu-
ated into 1 mg of lipids in NO-ELIP by using a relatively
ow pressure. We have also previously demonstrated that
urface modifications of ELIP with antibodies can target
LIP to inflamed arterial walls and localize the therapeutics
10). The NO-ELIP are echogenic and provide a means for
onitoring in the circulation and delivery of NO-ELIP
ith contrast-enhanced ultrasound imaging. As needed, a
apid but controlled payload release from ELIP can be
chieved by the use of Doppler ultrasound at a specific site
24). All the listed techniques have the potential to maxi-
uryr Balloon Injury
dial Area (mm2) Medial Depth (mm) I/M Ratio I/(IM)
0.42 0.03 0.12 0.01 1.1 0.14 0.5 0.04
0.44 0.04 0.13 0.004 1.1 0.15 0.5 0.08
0.45 0.03 0.12 0.01 0.5 0.03† 0.3 0.03†n InjAfte
Meinjury alone and Ar-containing liposomes.
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NO Liposomes for Hyperplasia Inhibition August 11, 2009:652–9ize the effects of drugs and/or bioactive gases in a localized
anner.
We have demonstrated that local administration of NO-
LIP is effective in reducing neointimal hyperplasia in
njured carotid arteries in hyperlipidemic rabbits. Such a
odel resembles the clinical situation of balloon angioplasty
n coronary and other vascular beds. The in vivo effect of
nhaled NO on neointimal hyperplasia has been inconsis-
ent. Lee et al. (25) have described a beneficial effect of
nhaled NO in reducing neointimal formation in balloon-
njured carotid arteries in rats. Others (26), however, have
een unable to demonstrate NO effects in the pulmonary
asculature.
Hemoglobin binding to inhaled NO is likely responsible
or the inability of NO to reach the intended vascular beds.
he affinity of NO for hemoglobin is 1,500 times greater
han that of carbon monoxide. It has been demonstrated
hat red blood cells, because of their high hemoglobin
ontent, can reversibly bind, transport, and release NO
ithin the cardiovascular system (27). In Figure 4, the
O/Ar-saturated mannitol solution was less efficient in
elivering NO to VSMCs than the NO/Ar-ELIP; both
ethodologies were rendered less effective for NO delivery
o VSMC in the presence of hemoglobin. However, Figures
A and 4D appear similar, and there is consistency between
he fluorescent enhancement of Figures 4B and 4D. This
nding clearly demonstrates the ability of the liposomes to
rotect NO from hemoglobin scavenging. This mixture of
O/Ar further modulates the rate of NO delivery into cells.
his experimental condition consisting of the presence of
emoglobin mimics local NO delivery by NO/Ar-ELIP in
ivo, and animal experiments also substantiate the biologic
ffects of NO/Ar-ELIP when delivered locally in balloon-
njured arteries (28).
tudy limitations. To demonstrate NO release, we deliv-
red NO-ELIP (without targeting) to an occluded artery
ocally. This method of delivery may mimic certain inter-
entions such as angioplasty of an occluded coronary or
arotid artery but may not simulate physiologic flow condi-
ions when arterial flow is present. Although we have
emonstrated the protective effects of NO encapsulation
nto liposomes for preventing NO scavenging by hemoglo-
in, we assume that continuous blood flow will probably
ncrease the scavenging effect of NO by hemoglobin. This
ay be overcome by local delivery of NO-ELIP, targeting of
he NO-ELIP, and ultrasound-enhanced NO release. Local
elivery of antiproliferative or immunosuppressive agents im-
ediately after angioplasty has been successful in clinical trials
nd has been proven more efficient compared with systemic
rug delivery (29).
Recently, Cyrus et al. (30) have developed a “contact
acilitated drug delivery” methodology to incorporate v3-
argeted nanoparticles containing rapamycin for targeting
nd content release through fusion of the lipid membrane
ith the targeted cell membrane. This methodology couldlso be useful in targeting and release of our NO-ELIP. Innother study, we have also found that local ultrasound
pplication enhances NO delivery to the arterial wall under
hysiological flow conditions, demonstrating another po-
ential methodology to increase NO delivery.
The spontaneous release pattern, in which release is
nitially rapid and then later much slower, may limit the
mount of gas deliverable to targeted sites, with the conse-
uence of reducing localized delivery and increasing sys-
emic exposure. Further modifications of the lipid shell
omposition as to make it less permeable and reduce
pontaneous gas release may overcome this problem. Surface
odifications of NO-ELIP such as the addition of poly-
thylene glycol and antibodies to the lipid shell to prolong
irculation duration and provide specific targeting mecha-
isms were not evaluated in this study.
Despite a lack of sophistication of our initial approaches,
arked in vivo effects were realized which induced inhibi-
ion of intima/media ratio by 40% by NO-ELIP in injured
rteries compared with Ar-ELIP or no treatment. Thera-
eutic effects should be improved by coencapsulating NO
ith other NO donors or synthetic genes involved in NO
ynthesis, although the benefit of such procedures must be
ssessed by future research.
onclusions
new technique has been described for encapsulating NO
nto liposomes for bioactive gas delivery. Such formulations
ave the desirable properties of high payload concentration,
odifiable gas release profiles, sufficient protection of the
O payload against exogenous scavengers, and excellent
ayload delivery to cells for biologic effects. With future
ormulation modifications, this methodology may expand
he repertoire of NO donors in the payload, providing
reater stability, as well as site-specific triggered delivery
ith ultrasound, to maximize bioactive effect at the local
issue level.
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